Alexza’s AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with … (The San Francisco Examiner)

MOUNTAIN VIEW, Calif. ( Map ) - MOUNTAIN VIEW , Calif., March 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today positive top-line results from its 168 patient Phase 2a clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache.

[News Source]